About eNeura
eNeura is a Healthcare company based in Baltimore (United States) founded in 2000. It operates as a transcranial magnetic stimulation devices for migraine treatment are developed. eNeura has raised $70.51 million across 18 funding rounds from investors including Orthofix, Camden Partners and NEA. The company has 17 employees. eNeura offers products and services including sTMS Device and SAVI Smart Diary. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is ENEURA, INC. Its competitors include ElectroCore, ShiraTronics, Salvia BioElectronics, Cefaly and Zosano Pharma and 4 more; 6 of its 9 listed competitors have raised funding.
Company details
eNeura was founded in 2000 and is headquartered in Baltimore, United States. Portable, non-invasive transcranial magnetic stimulation devices are developed by the company for migraine pain relief. An FDA-approved prescription device is provided, allowing patients to self-administer treatments as needed. Operations focus on neuromodulation technology within the medical device sector, targeting chronic headache management.
- Headquarters Baltimore, United States
- Employees 17
- SectorsHealthcare
- Website eneura.com
- Social LinkedIn Instagram
- Legal Name Eneura, Inc.
- Total Equity Funding$70.51M (USD)
in 18 rounds
- Latest Funding Round$511.04K (USD), Series D
Feb 2020
- InvestorsOrthofix
& 4 more
- Employee Count17
Products & Services of eNeura
eNeura offers a comprehensive portfolio of products and services, including sTMS Device and SAVI Smart Diary.
Non-invasive device that treats and prevents migraines using magnetic pulses.
App that automatically records and monitors migraine treatment history.
Funding Insights of eNeura
eNeura has successfully raised a total of $70.51M across 18 strategic funding rounds. The most recent funding activity was a Series D round of $511.04 thousand completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $70.51M
- Total Rounds 18
- Last Round Series D — $511,036
- First Round $7.6M
(Jan 2010)
- Investors Count 5
Latest 10 of 18 funding rounds of eNeura with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2020 | $511,036 | Series D | – | – | – |
| Nov 2019 | $5.91M | Debt – Conventional | – | – | – |
| Mar 2019 | $200,000 | Series D | – | – | – |
| Mar 2019 | – | Debt – Conventional | – | – | – |
| Nov 2018 | $13.45M | Series D | – | – | – |
| Feb 2018 | $17M | Series D | – | Camden Partners | – |
| Jul 2017 | $3.27M | Series D | – | – | – |
| Mar 2016 | $6.39M | Series D | – | – | – |
| Mar 2015 | $15M | Debt – Conventional | – | – | |
| Aug 2014 | $5.78M | Series C | – | – | – |
5 investors in total: 5 institutional.
Investors in eNeura
eNeura has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Orthofix, Camden Partners and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Growth equity investments are made in lower middle market companies. | 1995 | camdenpartners.com | Owings Mills, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Investments are made in US life sciences and energy companies. | – | technologypartners.com | Palo Alto, United States | |
Life science & tech focused VC firm investing in the US | – | domainvc.com | Princeton, United States | |
Reconstructive and regenerative solutions for bone conditions are developed. | 1980 | orthofix.com | Lewisville, United States |
Investor details for eNeura
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of eNeura
3 dated milestones of eNeura across 20 years, from founding to its latest funding, stage changes and deals.
- Founded eNeura is founded.
- Funding First funding round of $7.6M.
- Funding Latest funding round, Series D, of $511K.
Competitors of eNeura
eNeura has 9 listed competitors in our database, 6 of them funded. They include ElectroCore, ShiraTronics, Salvia BioElectronics, Cefaly and Zosano Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| electrocore.com | 2005 | Basking Ridge, United States | $161.39M | 58 | Non-invasive vagus nerve stimulation devices are developed for headache treatments. | |
| shiratronics.com | 2019 | Minneapolis, United States | $107.69M | – | Neuromodulation devices for migraine and chronic disease treatment are developed. | |
| salviabioelectronics.com | 2017 | Eindhoven, Netherlands | $88.4M | – | Bioelectronic solutions for migraines and neurological disorders are developed. | |
| cefaly.com | 2004 | Seraing, Belgium | – | 12 | Neurostimulation devices for migraine and headache treatment are provided. | |
| zosanopharma.com | 2006 | Fremont, United States | $147.16M | 40 | Develops innovative transdermal drug delivery technologies for various therapeutic applications. | |
| neurolief.com | 2012 | Herzliya, Israel | $5M | – | Wearable neuromodulation devices for neurological disorders are developed. | |
| chordate.com | 2005 | Kista, Sweden | – | – | Develops and markets CE-marked devices for migraine and rhinitis treatment. | |
| nocira.com | 2014 | Tempe, United States | $3.9M | – | Device for migraine management | |
| rehaler.io | 2009 | Aarhus, Denmark | – | – | A drug-free inhaler for migraine treatment is provided by Rehaler. |
Detailed competitors of eNeura
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of eNeura
The website of eNeura (eneura.com) receives about 4.2K visits a month.
- Monthly visits4.2K
▲ 52.5% vs previous month
Websites whose visitors overlap most with eNeura. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
acuderma.nl | acuderma.nl | 100% | – | – | – |
migraine-surgery-centre.com | migraine-surgery-centre.com | 100% | – | #7,716,063 | – |
Top companies in Pain Management
10 companies that operate in the same segment as eNeura (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eneura
Complete news archive for eNeura
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about eNeura
eNeura was founded in 2000 and raised its 1st funding round 10 years after it was founded.
eNeura is headquartered in Baltimore, United States. It is registered at Baltimore, Maryland, United States.
eNeura is a funded company, having raised a total of $70.51M across 18 funding rounds to date. The company's 1st funding round was a Series C of $5.78M, raised on Jan 2010.
eNeura has 17 employees.
eNeura was founded in 2000 and is headquartered in Baltimore, United States. Portable, non-invasive transcranial magnetic stimulation devices are developed by the company for migraine pain relief. An FDA-approved prescription device is provided, allowing patients to self-administer treatments as needed. Operations focus on neuromodulation technology within the medical device sector, targeting chronic headache management.
eNeura's top competitors include Salvia BioElectronics, ShiraTronics and ElectroCore.
eNeura offers sTMS Device and SAVI Smart Diary.
eNeura has 5 investors. Key investors include Orthofix, Camden Partners, NEA, Technology Partners, and Domain Associates.
eNeura operates through Eneura, Inc..